PNC-27 (30 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Critical: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established. Any dosing above a few hundred micrograms per day is purely speculative.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or colder (-80 °C ideal); short-term refrigeration at 2 to 8 °C acceptable.
• Reconstituted: refrigerate at 2 to 8 °C; use within approximately 30 days; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (PNC-27, 30 mg each):

• 8 weeks: ~1 vial. 12 weeks: ~1 vial. 16 weeks: ~2 vials.

Insulin Syringes (U-100 or 30/50-unit for precision):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 to 16 weeks: 1 bottle is sufficient.

Alcohol Swabs:

• 16 weeks: 224 swabs (3 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Regulatory Warning: PNC-27 has no FDA approval and no established human safety data.
• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• This information is strictly educational.

How This Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12-26) fused to a membrane-penetrating leader sequence. Preclinical studies indicate that PNC-27 selectively binds to HDM-2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Benefits & Side Effects

Observations from preclinical literature only; no human data available.

• Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM-2

while sparing normal cells.

• Mechanism involves direct membrane lysis rather than apoptosis in affected cells.
• No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been

established.

• Possible injection-site reactions (redness, irritation) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced, nutrient-dense diet to support overall metabolic function.
• Prioritize adequate sleep and stress management for immune and recovery support.
• Consult qualified healthcare professionals before any experimental peptide use.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. PNC-27 induces tumor cell membrane lysis (Cancer Chemotherapy and Pharmacology, 2010).
2. FDA Drug Safety Communication: PNC-27 is unapproved; safety not established (2015).